PAREXEL (PRXL) Gets CEO Cancer Gold Standard Accreditation

PAREXEL International Corporation (NASDAQ:PRXL) , a global biopharmaceutical services company and provider of clinical research and logistics, was recently nominated as a CEO Cancer Gold Standard employer by CEO Roundtable on Cancer.

Stock Performance

The price performance of PAREXEL International has been favorable in the last three months. The stock gained 42.95%, outperforming the Zacks classified Medical Services sub-industry’s gain of almost 6.02%. The current level compares favorably with the S&P 500’s return of 5.16% over the same time frame.

The estimate revision trend for the current year has been positive in the last two months. Two estimates moved south against six movements in the opposite direction.

Coming back to the news, the U.S.-based CEO Cancer Gold Standard biennial accreditation recognizes the company’s strong commitment to the health of its employees and their families. The CEO Roundtable on Cancer is a non-profit organization which is focused toward the development and implementation of initiatives that reduce cancer risks, enable early diagnosis and facilitate access to best available treatments. The organization strives toward the discovery of novel and effective therapies to help eliminate cancer as a personal disease and a public health problem.

Headquartered near Boston, MA, PAREXEL is a leading global biopharmaceutical services company. The company has offices in 86 locations in 51 countries and has approximately 19,600 employees.

PAREXEL is focused on expediting activities in growing areas like protocol design, study start-up, trial execution, regulatory submission and product commercialization. The company provides a broad range of clinical research, consulting, medical communications and technology solutions and services to pharmaceutical, biotechnology and medical device industries, worldwide. Per company estimate, the use of its services is helping its biopharmaceutical clients to complete clinical trials 22% faster than the industry average.

Going forward, we believe that the company is focused on diversifying its core business through the launches of branded data-driven services like Connected Journey. Meanwhile, the biopharmaceuticals market is anticipated to reach $278 billion by 2020 at a CAGR of 9.4%, per Persistence Market Research. We expect PAREXEL to gain significant traction in the biopharmaceutical and related ancillary markets, courtesy of the favorable trend and the takeover.

Zacks Rank & Key Picks

Currently, PAREXEL carries a Zacks Rank #3 (Hold).

Some better-ranked medical stocks are Mesa Laboratories, Inc. (NASDAQ:MLAB) , Edwards Lifesciences Corporation (NYSE:EW) and Align Technology, Inc. (NASDAQ:ALGN) . Notably, Mesa Laboratories and Edwards Lifesciences sport a Zacks Rank #1 (Strong Buy), while Align Technology carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Mesa Laboratories has a positive earnings surprise of 2.84% over the last four trailing quarters. The stock has added roughly 11.6% over the last three months.

Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has gained around 25.4% over the last three months.

Align Technology has an expected long-term adjusted earnings growth of almost 24.1%. The stock has added roughly 32.8% over the last three months.

More Stock News: 8 Companies Verge on Apple-Like Run

Did you miss Apple (NASDAQ:AAPL)'s 9X stock explosion after they launched their iPhone in 2007? Now 2017 looks to be a pivotal year to get in on another emerging technology expected to rock the market. Demand could soar from almost nothing to $42 billion by 2025. Reports suggest it could save 10 million lives per decade which could in turn save $200 billion in U.S. healthcare costs.

A bonus Zacks Special Report names this breakthrough and the 8 best stocks to exploit it. Like Apple in 2007, these companies are already strong and coiling for potential mega-gains. Click to see them right now >>